“It Is Time for Institutions to Take Responsibility and Commit to Promoting Academic Clinical Research”, says the NOVA Rector

21 de September, 2026

Strengthening investigator-initiated clinical research and creating the conditions required for its growth were at the centre of the PtCRIN’s CTU Impact Day, held at the Rectorate of Paulo Pereira’s NOVA University Lisbon, last Friday, 18th, and bringing together representatives from regulatory bodies, academic clinical centres, patient associations and European partners.

Opening the event, Paulo Pereira, Rector of NOVA University Lisbon, highlighted the strategic importance of academic clinical research for both the University and the national scientific system, noting that only around 3% of active clinical trials in Portugal are initiated by Portuguese entities.

Held under the theme Strengthening Investigator Initiated Clinical Trials, the event focused on the challenges and opportunities facing researcher-led studies. Paulo Pereira recalled NOVA’s longstanding involvement in PtCRIN, a national clinical research infrastructure that brings together 28 institutions, including hospitals, universities and research institutes, and highlighted the University’s contribution to its development since its inception.

The discussions also addressed the need to strengthen the support structures that enable high-quality clinical research. Particular attention was given to the role of organisations capable of assuming legal, regulatory and operational responsibilities, including sponsorship obligations, thereby reducing the administrative and legal burden placed on individual investigators.

In this context, the Rector called for a stronger institutional commitment to academic clinical research: “It is time for institutions to take responsibility and commit to promoting academic clinical research.”

Paulo Pereira stressed that, while Portugal has no shortage of scientific talent or relevant clinical questions, the country still faces structural challenges that limit the number of investigator-initiated trials. He argued that closer cooperation between universities, hospitals, regulators and funding bodies is essential to create the conditions needed for Portugal to play a more prominent role in leading clinical studies and generating research with a meaningful impact on society.